Eli Lilly’s Trulicity to top the GLP-1 market?
By Rajan Sharma, Senior Analyst
19 September 2014
I joined Datamonitor Healthcare in late in 2013 after completing a Masters in Pharmacology from the University of Oxford...
Read full bio
Eli Lilly’s Trulicity (dulaglutide) has, this week, been approved by the US FDA as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Our forecast report (click here to view) predicts that Trulicity will be the most prescribed GLP-1 agonist by 2022, surpassing current market leader Victoza (liraglutide; Novo Nordisk).
Once-weekly dosing, a convenient administration device, and good glycemic control gives Trulicity an advantage over earlier-to-market competitors such as Victoza, Bydureon (exenatide LAR; AstraZeneca) and Tanzeum (albiglutide; GlaxoSmithKline).
The launch of Trulicity comes very soon after GSK’s Tanzeum which was launched earlier this year. Both share a number of characteristics such as a once-weekly dosing schedule and administration via a small-gauge injection pen. Phase III clinical trial data indicate that Trulicity may be more effective than Tanzeum owing to its apparent greater control of HbA1c levels and weight-reducing properties. As such, Datamonitor Healthcare expects Trulicity to outperform Tanzeum in terms of sales revenue.
Datamonitor Healthcare analyst, Rajan Sharma, has forecast Trulicity revenues to overtake Novo Nordisk’s blockbuster once daily Victoza by 2022 across the US, Japan and five major EU markets by. By 2022 we predict Trulicity to achieve sales of $2,585million.
Trulicity currently is under review by the EMA and other regulatory bodies.
Posted in Metabolic.